Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curasept Prevent Probiotic is a dietary supplement developed by Curasept S.p.A. designed to support oral health by promoting eubiosis within the oral microbiome. It is formulated with specific probiotic strains, including *Bifidobacterium lactis* HN019 and *Kluyveromyces marxianus fragilis* B0399, along with supportive ingredients such as biotin and colostrum. The product is intended to prevent and manage periodontal diseases, including Stage I and II periodontitis, by balancing the bacterial flora and supporting the local immune response. In clinical research led by Massimo Corsalini, it is evaluated as part of a comprehensive oral hygiene regimen that includes ozonized olive oil-based toothpaste and mouthwash to improve clinical periodontal parameters.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curasept Prevent Probiotic.